Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Chemotherapy With or Without Radiation Therapy or Observation in Treating Young Patients With Advanced Retinoblastoma Who Have Undergone Surgery to Remove the Eye

Not Applicable

Conditions: Retinoblastoma

First Posted Date: 2006-08-07

Last Posted Date: 2013-09-17

Lead Sponsor: Children's Cancer and Leukaemia Group

Registration Number: NCT00360750

Locations: 🇬🇧
Leicester Royal Infirmary, Leicester, England, United Kingdom
🇬🇧
Royal Belfast Hospital for Sick Children, Belfast, Northern Ireland, United Kingdom
🇬🇧
Birmingham Children's Hospital, Birmingham, England, United Kingdom

and more 9 locations

Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site

Phase 2

Completed

Conditions: Neoplasm, Unknown Primary

Interventions: Drug: paclitaxel
Drug: carboplatin
Drug: bevacizumab
Drug: erlotinib

First Posted Date: 2006-08-04

Last Posted Date: 2013-12-04

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 60

Registration Number: NCT00360360

Locations: 🇺🇸
Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States
🇺🇸
Graves-Gilbert Clinic, Bowling Green, Kentucky, United States
🇺🇸
Oncology Hematology Associates of SW Indiana, Evansville, Indiana, United States

and more 6 locations

Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor

Phase 2

Terminated

Conditions: Lung Neoplasms

Interventions: Drug: Pemetrexed
Drug: carboplatin
Drug: gemcitabine

First Posted Date: 2006-07-26

Last Posted Date: 2010-08-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 41

Registration Number: NCT00356525

Locations: 🇮🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Trivandrum, India

Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma

Phase 1

Terminated

Conditions: Anaplastic Large Cell Lymphoma
Recurrent Childhood Anaplastic Large Cell Lymphoma

Interventions: Biological: monoclonal antibody SGN-30
Drug: therapeutic hydrocortisone
Drug: ifosfamide
Drug: carboplatin
Drug: etoposide
Drug: methotrexate
Drug: cytarabine
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2006-07-20

Last Posted Date: 2018-03-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 5

Registration Number: NCT00354107

Locations: 🇺🇸
Children's Oncology Group, Philadelphia, Pennsylvania, United States

A Phase II Study of Radiation Therapy, Paclitaxel Poliglumex, and Carboplatin in Stage III Non-Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Paclitaxel poliglumex
Drug: Carboplatin
Radiation: External beam radiation therapy

First Posted Date: 2006-07-17

Last Posted Date: 2016-12-12

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 10

Registration Number: NCT00352690

Locations: 🇺🇸
University of Kansas, Lawrence, Kansas, United States
🇺🇸
Rush University Medical College, Chicago, Illinois, United States
🇺🇸
Washington Hospital Center, Washington, District of Columbia, United States

and more 5 locations

ATN-161 and Carboplatin in Treating Patients With Recurrent Malignant Glioma

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

Interventions: Drug: ATN-161
Drug: carboplatin

First Posted Date: 2006-07-14

Last Posted Date: 2012-05-02

Lead Sponsor: National Institutes of Health Clinical Center (CC)

Target Recruit Count: 82

Registration Number: NCT00352313

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States

Vinblastine and Carboplatin in Treating Young Patients With Newly Diagnosed or Recurrent Low-Grade Glioma

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors
Neurofibromatosis Type 1

Interventions: Drug: carboplatin
Drug: vinblastine sulfate

First Posted Date: 2006-07-14

Last Posted Date: 2014-02-13

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 26

Registration Number: NCT00352495

Locations: 🇺🇸
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States
🇺🇸
SUNY Upstate Medical University Hospital, Syracuse, New York, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

and more 18 locations

Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer

Phase 1

Completed

Conditions: Neutropenia
Infectious Disorder
Stage IV Ovarian Cancer
Fallopian Tube Carcinoma
Ovarian Carcinosarcoma
Primary Peritoneal Carcinoma
Stage III Ovarian Cancer

Interventions: Procedure: Adjuvant Therapy
Drug: Carboplatin
Drug: Paclitaxel
Biological: Pegfilgrastim

First Posted Date: 2006-07-14

Last Posted Date: 2014-12-31

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 43

Registration Number: NCT00352300

Locations: 🇺🇸
Cooper Hospital University Medical Center, Camden, New Jersey, United States
🇺🇸
Riverside Methodist Hospital, Columbus, Ohio, United States
🇺🇸
Lake University Ireland Cancer Center, Mentor, Ohio, United States

and more 8 locations

Pemetrexed/Carboplatin Non-Small Cell Lung Cancer (NSCLC) Elderly Patients

Phase 2

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: pemetrexed
Drug: carboplatin

First Posted Date: 2006-07-11

Last Posted Date: 2010-10-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 62

Registration Number: NCT00350792

Locations: 🇫🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vandoeuvre Les Nancy, France

Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer

Phase 3

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Paclitaxel
Drug: NOV-002
Drug: Carboplatin

First Posted Date: 2006-07-04

Last Posted Date: 2022-07-25

Lead Sponsor: Cellectar Biosciences, Inc.

Target Recruit Count: 903

Registration Number: NCT00347412

Locations: 🇵🇱
Oddzial Chemioterapii Zaklad Opieki Zdrowotnej MSWiA, Olsztyn, Poland
🇵🇱
Oddzial Gruzlicy I Chorob Pluc I P, Prabuty, Poland
🇷🇴
Institute of Oncology, Department of Medical Oncology II, Bucharest, Romania

and more 72 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy